Belatacept Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
This Belatacept Drug Asset Due Diligence Report was built with PatSnap Life Sciences MCP workflows. Drug & Asset MCP establishes identity, ownership and stage; Clinical Trials MCP checks design, endpoints and readouts; Company & Deal Intelligence MCP reconstructs transaction precedent. Explore the MCP servers used in this report.
Decision date: 15 July 2026. Currency fields are presented in US$ millions as returned by the deal dataset. This is a screening memorandum, not legal, medical, patent or investment advice.
Approved
Highest phase
82
Registered trials
56
Result records
12
Matched deals
Executive recommendation: GO
Decision memo
Advance diligence: development maturity and available evidence support continued investment, subject to indication-specific safety, IP, and commercial gates.
The central underwriting question is whether Belatacept can convert its Fc fusion protein profile and CD80 x CD86 biology into clinically meaningful differentiation while preserving an investable safety, IP and commercial position.
1. Asset identity and development status
| Asset | Belatacept (query alias: belatacept) |
|---|---|
| Modality / target | Fc fusion protein; CD80 x CD86; CD80 inhibitors, CD86 inhibitors |
| Highest global status | Approved |
| Originator | Bristol Myers Squibb Co. |
| Active developers | Bristol Myers Squibb Co., Bristol-Myers Squibb Pharma EEIG, Bristol-Myers Squibb Australia Pty Ltd. |
The MCP disease footprint includes Renal transplant rejection, Allograft Rejection, Cardiac transplant rejection. The highest-phase flag is a useful orientation point, but the licensing case depends on indication-level evidence and rights, not the global label alone.
2. Clinical program: design and endpoint audit
| Registry | Phase | Status | Enrollment | Lead primary endpoint |
|---|---|---|---|---|
| NCT06291103 | Phase 2/3 | Not yet recruiting | 290 | The efficacy of belatacept combined with standard of care, compared to calcineurin inhibitors (CNI) combined with standard of care, among kidney transplant recipients with sABMR |
| NCT06478017 | Phase 2 | Recruiting | 66 | Proportion of subjects who experience acute cellular rejection (ACR) >ISHLT 2R (local or core read), hemodynamic compromise (HDC) rejection in the absence of a biopsy or histological rejection, re-transplantation, or death as a composite endpoint. |
| NCT06918990 | Phase 1 | Recruiting | 25 | Proportion of subjects who do not meet a stopping rule for safety and remain free of all of the following: Grade 3 or higher infusion reaction, Grade 3 or higher infections, and any malignancy excluding localized non-melanomatous skin cancer. |
The trial set should be diligenced for randomization, comparator relevance, endpoint hierarchy, analysis population, multiplicity, geographic mix and readout timing. For early-stage studies, safety and dose selection can be as decision-critical as response rate.
Reproduce the asset-to-trial workflow with PatSnap MCP
3. Clinical readouts: what is known
Simplified Immunosuppression with Belatacept and Once-Daily Azathioprine and Prednisone in Pediatric Kidney Transplantation
Not Applicable; n=5; evaluation: Positive. Reported fields: AE = One recipient discontinued belatacept after 11 months due to infusion-related dizziness and post-infusion somnolence; no other adverse effects were observed.
#1990 Safety of continued belatacept treatment after kidney graft rejection
Not Applicable; n=101; evaluation: Positive. Reported fields: Dialysis-free survival(3-year, secondary endpoint) = 97.9 % ( 93.8 - 100.0); Dialysis-free survival(3-year, secondary endpoint) = 87.6 % ( 78.8 - 97.5)
Donor-specific Mesenchymal Stem Cell Infusion in Human and Non-human Primate Kidney Transplantation
Phase 1; n=not disclosed; evaluation: Negative. Reported fields: Adverse Event: Acute Consequences of Donor-MSC Infusion = Donor-MSC infusion was acutely well-tolerated in humans and NHPs
These fields are structured evidence signals, not a substitute for statistical review. The next diligence pass should reconcile denominators, confidence intervals, follow-up, censoring, dose cohorts and treatment-emergent toxicity against the original abstract, registry and protocol.
4. Market and competitive position
Belatacept addresses Renal transplant rejection, Allograft Rejection, Cardiac transplant rejection. Commercial attractiveness rests on addressable biomarker-positive patients, treatment-line placement, duration, administration burden, pricing and displacement of entrenched standards. The modality—Fc fusion protein—must demonstrate a benefit large enough to offset class-specific safety and operational costs.
The strongest market-validation signal in this screen is partner behavior: 12 matched transaction record(s) indicate that sophisticated counterparties have assigned strategic value to the asset or its rights. That does not establish net present value; probability of success, remaining R&D spend, royalties, cost sharing and territorial scope still need modeling.
5. Transaction precedent and economics
Transaction-scope note: No direct asset-specific transaction was returned. The table below shows target-level comparable: CD80 x CD86 records as comparable precedents only.
| Date | Transaction | Phase at deal | Disclosed economics |
|---|---|---|---|
| 2024-05-28 | BriaCell Announces Clinical Supply Agreement with BeiGene for Bria-OTS™ First in Human Study | Preclinical | Financial terms not disclosed |
| 2023-03-20 | Coya Therapeutics, Inc. Announces an Agreement with Dr. Reddy’s Laboratories, Ltd. to License its proposed biosimilar Abatacept for the Development and Commercialization of COYA 302 for the Treatment of Neurodegenerative Diseases | Preclinical | Financial terms not disclosed |
| 2021-03-23 | The Zenas pipeline also includes three potentially best-in-class mAbs (ZB002, ZB003, ZB004) exclusively in-licensed worldwide from Xencor, Inc. | Phase 2 | US$480.0M milestones |
Headline values are not directly comparable. Diligence should normalize upfront cash, equity, development and sales milestones, tiered royalties, opt-in mechanics, cost sharing, change-of-control clauses and geography.
6. IP and freedom-to-operate screen
No asset-specific patent-application milestone appeared in the returned milestone slice. That absence is not a freedom-to-operate conclusion; a dedicated family, claim, ownership, expiry, and legal-status search remains mandatory before signing.
The claim chart should separately test composition or sequence coverage, formulation and dosing, indication and biomarker claims, combinations, manufacturing know-how, prosecution history, term extensions and third-party blocking rights. Confirm that licensed patents, data and know-how track every granted territory and field.
7. Principal risks and diligence gates
- Class crowding and differentiation versus other PD-(L)1/VEGF agents
- Immune and anti-angiogenic safety, including bleeding and cardiovascular risk
- Biomarker strategy, indication selection, and head-to-head endpoint execution
Cross-functional diligence should also test CMC comparability, supply chain, pharmacovigilance, regulatory correspondence, data integrity, investigator concentration, partner obligations and change-of-control restrictions.
8. Final go/no-go memorandum
GO
Advance diligence: development maturity and available evidence support continued investment, subject to indication-specific safety, IP, and commercial gates.
Required pre-signing gates: reproduce key efficacy analyses; complete an indication-specific safety review; run a full patent-family and freedom-to-operate search; model risk-adjusted economics by territory; and reconcile all rights, sublicenses and encumbrances.
Build your next drug-asset diligence workflow with PatSnap Life Sciences MCP Servers
Data provenance: PatSnap Drug & Asset MCP, Clinical Trials MCP, and Company & Deal Intelligence MCP; accessed 15 July 2026. Counts and status fields may change as source records update.
